Jefferies Financial Group Cuts Sangamo Therapeutics (NASDAQ:SGMO) Price Target to $3.00

Sangamo Therapeutics (NASDAQ:SGMO) had its target price reduced by Jefferies Financial Group from $7.00 to $3.00 in a research report sent to investors on Tuesday morning,Benzinga reports. They currently have a buy rating on the biopharmaceutical company’s stock.

A number of other research firms also recently weighed in on SGMO. Wells Fargo & Company reduced their target price on shares of Sangamo Therapeutics from $3.00 to $2.00 and set an “equal weight” rating on the stock in a research report on Tuesday. Barclays upped their price objective on shares of Sangamo Therapeutics from $3.00 to $9.00 and gave the stock an “overweight” rating in a report on Thursday, November 14th. StockNews.com lowered shares of Sangamo Therapeutics from a “buy” rating to a “hold” rating in a report on Tuesday, December 24th. HC Wainwright restated a “buy” rating and issued a $10.00 price target on shares of Sangamo Therapeutics in a research note on Thursday, December 19th. Finally, Truist Financial upgraded Sangamo Therapeutics from a “hold” rating to a “buy” rating and set a $7.00 price objective for the company in a research note on Friday, December 13th. Three analysts have rated the stock with a hold rating and four have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $5.50.

Sangamo Therapeutics Price Performance

Shares of SGMO opened at $1.13 on Tuesday. The company has a 50-day simple moving average of $2.14 and a two-hundred day simple moving average of $1.22. The firm has a market capitalization of $235.77 million, a PE ratio of -1.51 and a beta of 1.15. Sangamo Therapeutics has a one year low of $0.30 and a one year high of $3.18.

Sangamo Therapeutics (NASDAQ:SGMO) last released its earnings results on Tuesday, November 12th. The biopharmaceutical company reported $0.04 EPS for the quarter, beating analysts’ consensus estimates of ($0.03) by $0.07. The company had revenue of $49.41 million during the quarter, compared to analysts’ expectations of $26.55 million. Sangamo Therapeutics had a negative return on equity of 264.16% and a negative net margin of 257.87%. During the same quarter last year, the business posted ($0.34) EPS. Analysts expect that Sangamo Therapeutics will post -0.46 EPS for the current fiscal year.

Institutional Investors Weigh In On Sangamo Therapeutics

Several institutional investors and hedge funds have recently made changes to their positions in the company. Cubist Systematic Strategies LLC bought a new position in Sangamo Therapeutics in the 2nd quarter valued at approximately $67,000. Meritage Portfolio Management boosted its position in shares of Sangamo Therapeutics by 8.6% during the third quarter. Meritage Portfolio Management now owns 85,000 shares of the biopharmaceutical company’s stock valued at $74,000 after buying an additional 6,740 shares during the last quarter. Point72 Asia Singapore Pte. Ltd. bought a new stake in Sangamo Therapeutics in the 2nd quarter worth about $89,000. XTX Topco Ltd increased its holdings in Sangamo Therapeutics by 167.8% in the 3rd quarter. XTX Topco Ltd now owns 103,716 shares of the biopharmaceutical company’s stock worth $90,000 after buying an additional 64,981 shares in the last quarter. Finally, Wealth Enhancement Advisory Services LLC lifted its stake in Sangamo Therapeutics by 55.4% during the 3rd quarter. Wealth Enhancement Advisory Services LLC now owns 108,945 shares of the biopharmaceutical company’s stock valued at $94,000 after acquiring an additional 38,850 shares during the period. Institutional investors own 56.93% of the company’s stock.

Sangamo Therapeutics Company Profile

Sangamo Therapeutics, Inc, a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company's clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; TX200, a chimeric antigen receptor engineered regulatory T cell (CAR-Treg) therapy product candidate that is in Phase 1/2 clinical study for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation; SB-525, a gene therapy product candidate, which is in Phase 3 clinical trial for the treatment of moderately severe to severe hemophilia A; BIVV003, a zinc finger nuclease gene-edited cell therapy product candidate that is in Phase 1/2 PRECIZN-1 clinical study for the treatment of sickle cell disease.